Applied Therapeutics Inc (APLT) has released an update.
Applied Therapeutics, Inc. has announced promising interim results from their Phase 3 INSPIRE trial for govorestat (AT-007), a potential treatment for SORD Deficiency—a genetic neuropathy with no current treatment options. The 12-month data shows that govorestat significantly reduces toxic sorbitol levels, correlating with improvements in mobility and quality of life for patients. With these positive outcomes, the company is considering discussing a New Drug Application with the FDA, signaling hope for those affected by this debilitating condition.
For further insights into APLT stock, check out TipRanks’ Stock Analysis page.
